[The pharmaco-economics of the treatment of arterial hypertension: data and controversies].
The cost benefit ratio of antihypertensive therapy motivated many researches and discussions these last years. The treatment of this very frequent and chronic abnormality is of importance in this time of shortage of money available for health care. Its cost benefit ratio appears to decrease with age and the severity of hypertension: but these calculations rest on several hypotheses, that need scientific demonstrations by prospective data retrieval.
Rorive
G
G
Service de Néphrologie et de Pharmacie hospitalière, C.H.U.-Université de Liège au Sart-Tilman.
Delporte
J P
JP
D000367:Age Factors; D000959:Antihypertensive Agents / Q000191:economics* / Q000627:therapeutic use; D002908:Chronic Disease; D003362:Cost-Benefit Analysis; D018450:Disease Progression; D016527:Drug Costs; D017850:Economics, Pharmaceutical; D017048:Health Care Costs; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000191:economics / Q000503:physiopathology
D000959:Antihypertensive Agents